Chao Family Comprehensive Cancer Center

University of California, Irvine

Orange, CA

Accepting patients

SELECT MDS-1

A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Tamibarotene Plus Azacitidine Versus Placebo Plus Azacitidine in Newly Diagnosed, Adult Patients Selected for RARA-positive Higher-risk Myelodysplastic Syndrome (SELECT MDS-1)
Learn more
  • Hypomethylating Agents (HMA)
  • RAR-α / NR1B1
  • Phase 3

Accepting patients

R289

Phase 1b Study of R289 in Patients with Lower-risk Myelodysplastic Syndromes (LR MDS)
Learn more
  • IRAK 1 Inhibitor
  • IRAK 4 Inhibitor
  • Phase 1/2
All clinical trials have eligibility criteria - or a list of reasons why you may be able or unable to participate in a trial. Answer a few questions to view your personalized results - all in under 60 seconds.
Help me find trials

Accepting patients

Venetoclax in Combination With ASTX727, an All-ORal Therapy for Chronic Myelomonocytic Leukemia and Other MDS/MPN With Excess Blasts (VICTORY-MDS/MPN): A Randomized, Phase 2 Trial
Learn more
  • BCL-2 Inhibitor
  • Hypomethylating Agents (HMA)
  • Phase 2

Accepting patients

ACROBAT

Assessment of Chimerism and Relapse Post Bone Marrow/HCT Transplant Using AlloHeme Test
Learn more
  • Laboratory Assay
  • Observational Trial

Accepting patients

GLB-100

A First-in-human, Phase 1, Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic Syndromes
Learn more
  • Cyclin-Dependent Kinase Inhibitor (CDK Inhibitor)
  • High Risk
  • Phase 1